Figure 7.
Figure 7. Adoptive transfer of splenocytes from hemophilia B C3H/HeJ mice, which had received intranasal administration of peptide 2A-54 and hepatic AAV-hF.IX gene transfer (□). Recipients were naive wild-type C3H/HeJ mice, and controls (▴) received splenocytes from other naive wild-type C3H/HeJ mice. All recipients were immunized with hF.IX in cFA 36 hours after adoptive transfer. Shown are average anti-hF.IX IgG titers ± SD for cohorts of mice that had received CD4–, CD4+, CD4+CD25+, or CD4+CD25– cells (2.5 weeks after immunization, n = 4-5 per experimental cohort).P values are indicated.

Adoptive transfer of splenocytes from hemophilia B C3H/HeJ mice, which had received intranasal administration of peptide 2A-54 and hepatic AAV-hF.IX gene transfer (). Recipients were naive wild-type C3H/HeJ mice, and controls (▴) received splenocytes from other naive wild-type C3H/HeJ mice. All recipients were immunized with hF.IX in cFA 36 hours after adoptive transfer. Shown are average anti-hF.IX IgG titers ± SD for cohorts of mice that had received CD4, CD4+, CD4+CD25+, or CD4+CD25 cells (2.5 weeks after immunization, n = 4-5 per experimental cohort).P values are indicated.

Close Modal

or Create an Account

Close Modal
Close Modal